Atlas Trials

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Clinical trial NCT03356860 · COMPLETED

Trial details

NCT number
NCT03356860
Sponsor
Grand Hôpital de Charleroi
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast CancerTriple Negative Breast CancerLuminal B
Start date
2017-04-13
Primary completion
2022-11-21
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.